Neuroendocrine Prostate Cancer Epidemiology

Neuroendocrine Prostate Cancer (NEPC) Insights and Trends

• According to DelveInsight’s analysis, the total incident cases of NEPC were ~ 24,500 in the 7MM (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
• NEPC is associated with rapid progression, early visceral metastasis, and poor survival, resulting in a substantially higher clinical burden than conventional prostate adenocarcinoma.
• T-NEPC represents the predominant subtype, whereas de novo NEPC accounts for only a small proportion of incident prostate cancer cases. The increasing use of androgen receptor pathway inhibitors and improved survival in advanced prostate cancer are expected to further increase the burden of treatment-emergent disease during the forecast period.
• Definitive diagnosis relies on metastatic tissue biopsy with immune-histochemical markers (e.g., synaptophysin, chromogranin A, CD56, and NSE), as no validated serum biomarker or imaging modality can independently confirm NEPC.
• Conventional diagnostic tools have limited utility in NEPC. Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) sensitivity is reduced due to loss of PSMA expression, while PSA often remains low despite extensive metastatic disease, contributing to delayed diagnosis and under-recognition.
• NEPC remains substantially underdiagnosed in routine clinical practice because diagnosis depends on histopathological confirmation from metastatic tumor biopsies, which are infrequently performed in patients with advanced mCRPC due to their invasive nature and limited perceived clinical benefit. Consequently, the true prevalence of NEPC is likely underestimated.
• Increasing recognition of t-NEPC, improved molecular diagnostics, widespread use of androgen receptor-targeted therapies, and the growing burden of metastatic castration-resistant prostate cancer (mCRPC) are expected to drive the NEPC burden over the next decade. Advancing early diagnosis, biomarker-guided patient selection, and targeted therapies will remain key determinants of future market growth.

Neuroendocrine Prostate Cancer (NEPC) Epidemiology Forecast in 7MM

• 2025 Incident Cases of NEPC: ~ 24,500
• Projected 2036 Incident Cases of NEPC: ~ 28,300
• NEPC Growth Rate (2026–2036): ~1.3% CAGR

DelveInsight's ‘Neuroendocrine Prostate Cancer (NEPC) – Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the NEPC, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Neuroendocrine Prostate Cancer (NEPC) Understanding and Diagnosis Algorithm

NEPC Overview and Diagnosis

NEPC is a rare and highly aggressive subtype of prostate cancer characterized by neuroendocrine differentiation and loss of androgen receptor signaling. It most commonly develops as a treatment-emergent disease following prolonged androgen deprivation therapy (ADT) and androgen receptor pathway inhibitor (ARPI) treatment in patients with metastatic castration-resistant prostate cancer (mCRPC), although it can rarely occur as de novo disease. NEPC is associated with rapid progression, frequent visceral metastases, poor prognosis, and limited treatment options, with platinum-based chemotherapy remaining the current standard of care.

NEPC is diagnosed through clinical evaluation, histopathological examination, immune-histochemical (IHC) assessment, and molecular characterization. Diagnostic evaluation typically includes serum prostate-specific antigen (PSA) and neuroendocrine biomarkers (e.g., chromogranin A, synaptophysin, and neuron-specific enolase), multipara metric imaging, tissue biopsy with histopathological confirmation, and IHC staining for neuroendocrine markers. In selected cases, molecular profiling and liquid biopsy may be performed to identify genomic alterations, assess lineage plasticity, and guide therapeutic decision-making.

Further details are provided in the report.

Neuroendocrine Prostate Cancer (NEPC) Epidemiology

Key Findings from Neuroendocrine Prostate Cancer (NEPC) Epidemiological Analysis and Forecast

• According to DelveInsight’s estimates, the total incident cases of NEPC in the 7MM were approximately 24,500 in 2025.
• Among the EU4, Germany accounted for the highest number of incident cases of NEPC, followed by France, whereas Spain accounted for the lowest number of cases in 2025.
• In 2025, distant-stage disease accounted for 78% of the incident NEPC population in the United States, followed by early stage (22%) disease. This stage distribution is expected to remain largely stable through 2036, with distant-stage disease continuing to represent the majority of cases.
• In 2025 in Japan, patients aged >65 years accounted for the largest number of incident NEPC cases (approximately 1,770 cases), followed by those aged 60–65 years (approximately 1,000 cases) and aged <60 years with 757 cases.
• Approximately 18,600 incident cases of NEPC patients were estimated to express DLL3 in 2025 across the 7MM, highlighting a substantial biomarker-defined population eligible for emerging targeted therapies.

Scope of the Report

• The report covers a segment of an executive summary, a descriptive overview of NEPC, explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

• Neuroendocrine Prostate Cancer (NEPC) Patient Population Forecast

Report Key Strengths

• Epidemiology-based (epi-based) Bottom-up Forecasting
• 11-year Forecast
• Patient Burden Trends (by geography)

FAQs

• What are the disease risks, burdens, and unmet needs of NEPC? What will be the growth opportunities across the 7MM concerning the patient population with NEPC?
• What is the historical and forecasted NEPC patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.